Isomorphic Labs has closed a $2.1 billion Series B round to expand its AI-driven drug discovery platform and move therapeutic programs toward clinical development. The spinout from Google DeepMind will use the capital to scale its IsoDDE drug design engine, grow scientific teams and accelerate candidate progression.
Major Investment Fuels AI-Powered Drug Design
Isomorphic Labs’ Mission
Founded from DeepMind research, Isomorphic Labs applies machine learning to predict protein structures and design small molecules and biologics. Its IsoDDE engine integrates structural models with generative design to propose and prioritise candidate compounds, reducing the time between target identification and lead optimisation.
Strategic Capital for IsoDDE
The $2.1 billion will be directed at refining IsoDDE, expanding datasets and compute capacity, and recruiting multidisciplinary teams across biology, chemistry and engineering. The funding is intended to accelerate multiple therapeutic programs through preclinical stages and toward first-in-human trials, compressing timelines that traditionally take years.
Investors and Industry Impact
Key Backers and UK Involvement
Lead investors include Thrive Capital alongside continued support from Alphabet and GV. Other backers named in the round include MGX, Temasek, CapitalG and the UK’s sovereign AI fund. The mix of technology and life sciences investors signals strong market confidence in AI-native drug development approaches.
Shaping Medicine’s Future
Beyond funding a single company, this round marks a milestone for the AI-in-healthcare sector. It reflects growing investor willingness to fund long-horizon biological drug development driven by machine learning. For pharmaceutical companies and biotech investors, Isomorphic Labs’ scale-up offers a test case for how AI can compress R&D cycles, increase prediction accuracy, and diversify the pipeline of candidates entering clinical evaluation.
Previously supported by Alphabet and early private investors after its DeepMind origins, this Series B places Isomorphic Labs among the best-funded AI drug discovery ventures, and sets expectations for faster iteration from model to molecule.
